



28 November 2018

**ACW 2018 AGM Chairman's address**

Good morning everybody.

My name is Geoff Brooke and I am the chair of Actinogen Medical Limited.

A warm welcome to the 2018 AGM for all attendees, especially our shareholders, long standing, as well as new. Many thanks for your attendance.

I would like to introduce the members of the Actinogen board and senior executives.

I welcome Dr George Morstyn, who joined the board immediately following the 2017 AGM and in accordance with ASX rules is standing today for re-election. George is one of Australia's best qualified biotech company directors and drug developer, having been Chief Medical Officer of the world's largest biotech company, Amgen Inc. I have known George for around 20 years and we are very lucky to have him involved.

I also welcome our CEO, Dr Bill Ketelbey, who will address the shareholders shortly. Also present from the Company are Vincent Ruffles and Tamara Miller who head up our drug development program.

I also acknowledge our Company Secretary, Mr Peter Webse and also Mr Timothy Dachs who is representing Ernst & Young, the Company's auditor.

This year has been a watershed year for Actinogen, where we have achieved a number of major milestones.

As Bill will discuss in greater detail in a moment, the Company has recently completed enrolling XanADu, our phase II clinical trial in mild Alzheimer's disease patients. In fact, it was extremely encouraging to see the trial completed ahead of schedule and be over-subscribed in terms of patient numbers.

2018 also saw us add 3 major institutional investors to our shareholder register in a midyear Placement, where we were able to raise sufficient funds to undertake several value adding ancillary development studies to our already intense drug program.

In addition to this new strong institutional presence on the register, we have a highly supportive investor base, with many existing shareholders opting to participate in the Share Purchase Plan, which closed post the fiscal year end.

In ongoing support of the development of Xanamem, our lead drug candidate, independent research published during the year provided further endorsement of the cortisol hypothesis. Research recently published in esteemed journals such as Nature and Neurology point to an association between high cortisol levels and cognitive decline, we believe supporting the Actinogen premise that reducing cortisol in certain Alzheimer's patients may improve their condition.

Never before has there been such an urgency to develop, and bring to market, a new therapy for the treatment of Alzheimer's disease. This year, Alzheimer's disease became the leading cause of death in Australian women and the second leading cause of death overall. The importance of the development of a drug such as Xanamem cannot be overstated as it is imperative to find a new treatment for this devastating disease.

In closing, once again, I'd like to take this opportunity to thank all our shareholders for their continued support of the Company's endeavours.

I'd also like to take this opportunity to thank all our staff and partners for their ongoing hard work and dedication, and to my fellow Board members for their commitment to Actinogen Medical. In particular, I would like to thank retiring director, Dr Jason Loveridge, who was instrumental in the creation of Actinogen Medical and has added significant value to the Company over the past several years.

I will now hand over to our CEO, Dr Bill Ketelbey for him to present the Company's progress for 2018 and plans for 2019 in more detail.

## **ENDS**

### **Actinogen Medical**

Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: bill.ketelbey@actinogen.com.au  
 @BillKetelbey

### **Investor and Media Enquiries**

Ben Walsh  
WE Buchan  
M: +61 411 520 012  
E: bwalsh@we-buchan.com

## **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

## **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - through the inhibition of the 11 $\beta$ -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death - all hallmarks of Alzheimer's disease.

## **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**